Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) — free guideline decision tool
Predict suboptimal primary cytoreduction (residual > 1 cm) risk in advanced ovarian cancer from pre-operative CT findings, CA-125 and clinical factors. Instant, browser-side.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Age ≥ 60 years (+1) | No |
|---|---|
| CA-125 ≥ 500 U/mL (+1) | No |
| Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) | No |
| Diffuse small-bowel adhesions/thickening (+1) | No |
| Perisplenic lesion > 1 cm (+2) | No |
| Small-bowel mesentery lesion > 1 cm (+2) | No |
| Lesion at the root of the superior mesenteric artery > 1 cm (+2) | No |
| ASA class 3–4 (+3) | No |
| Lesser-sac lesion > 1 cm (+4) | No |
→Suidan score0 pts
- Total：0 pts (band 0) → suboptimal cytoreduction (residual > 1 cm) rate ~ 5%
- Scored items：No positive items (0 pts)
- Clinical note：Low suboptimal risk: favour primary debulking surgery (PDS) provided optimal cytoreduction is achievable
| Age ≥ 60 years (+1) | Yes |
|---|---|
| CA-125 ≥ 500 U/mL (+1) | Yes |
| Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) | Yes |
| Diffuse small-bowel adhesions/thickening (+1) | Yes |
| Perisplenic lesion > 1 cm (+2) | Yes |
| Small-bowel mesentery lesion > 1 cm (+2) | Yes |
| Lesion at the root of the superior mesenteric artery > 1 cm (+2) | Yes |
| ASA class 3–4 (+3) | Yes |
| Lesser-sac lesion > 1 cm (+4) | Yes |
→Suidan score17 pts
- Total：17 pts (band ≥ 9) → suboptimal cytoreduction (residual > 1 cm) rate ~ 74%
- Scored items：Age ≥ 60 (+1), CA-125 ≥ 500 (+1), suprarenal nodes > 1 cm (+1), diffuse small-bowel adhesions/thickening (+1), perisplenic > 1 cm (+2), small-bowel mesentery > 1 cm (+2), SMA root > 1 cm (+2), ASA 3–4 (+3), lesser sac > 1 cm (+4)
- Clinical note：High suboptimal risk: favour neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS), or refer to an experienced gyn-onc centre / laparoscopic assessment (e.g. Fagotti score) before deciding
Common questions
What is Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction)?
Predict suboptimal primary cytoreduction (residual > 1 cm) risk in advanced ovarian cancer from pre-operative CT findings, CA-125 and clinical factors. Instant, browser-side.
How is Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) calculated? What is the core formula?
Weighted sum: lesser sac +4; ASA 3–4 +3; perisplenic / small-bowel mesentery / SMA root each +2; age ≥ 60 / CA-125 ≥ 500 / suprarenal nodes / diffuse small bowel each +1. Bands 0 → ~ 5%, up to ≥ 9 → ~ 74% suboptimal.
When is Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) used?
Support the primary-debulking vs neoadjuvant-chemotherapy decision in advanced ovarian/tubal/peritoneal cancer.
What are the key clinical points for Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction)?
The model uses pre-operative abdominopelvic CT plus CA-125 and clinical factors, with predictive accuracy around 0.76. Higher scores (≥ 7, suboptimal rate ≥ 52%) favour neoadjuvant chemotherapy + interval debulking or referral to an experienced centre. It is decision-support, not a hard cut-off — combine with performance status, surgeon experience and multidisciplinary input. The CA-125 ≥ 500 U/mL threshold is specific to this model.
What are the limits and cautions when using Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) calculated in practice? Can you show a worked example?
Inputs: Age ≥ 60 years (+1) No, CA-125 ≥ 500 U/mL (+1) No, Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) No, Diffuse small-bowel adhesions/thickening (+1) No, Perisplenic lesion > 1 cm (+2) No, Small-bowel mesentery lesion > 1 cm (+2) No, Lesion at the root of the superior mesenteric artery > 1 cm (+2) No, ASA class 3–4 (+3) No… → Result: Suidan score 0 pts（Total: 0 pts (band 0) → suboptimal cytoreduction (residual > 1 cm) rate ~ 5%, Scored items: No positive items (0 pts), Clinical note: Low suboptimal risk: favour primary debulking surgery (PDS) provided optimal cytoreduction is achievable） Inputs: Age ≥ 60 years (+1) Yes, CA-125 ≥ 500 U/mL (+1) Yes, Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) Yes, Diffuse small-bowel adhesions/thickening (+1) Yes, Perisplenic lesion > 1 cm (+2) Yes, Small-bowel mesentery lesion > 1 cm (+2) Yes, Lesion at the root of the superior mesenteric artery > 1 cm (+2) Yes, ASA class 3–4 (+3) Yes… → Result: Suidan score 17 pts（Total: 17 pts (band ≥ 9) → suboptimal cytoreduction (residual > 1 cm) rate ~ 74%, Scored items: Age ≥ 60 (+1), CA-125 ≥ 500 (+1), suprarenal nodes > 1 cm (+1), diffuse small-bowel adhesions/thickening (+1), perisplenic > 1 cm (+2), small-bowel mesentery > 1 cm (+2), SMA root > 1 cm (+2), ASA 3–4 (+3), lesser sac > 1 cm (+4), Clinical note: High suboptimal risk: favour neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS), or refer to an experienced gyn-onc centre / laparoscopic assessment (e.g. Fagotti score) before deciding）
Run Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) now
Predict suboptimal primary cytoreduction (residual > 1 cm) risk in advanced ovarian cancer from pre-operative CT findings, CA-125 and clinical factors. Instant, browser-side.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.